Zevtera® is the commercial brand name of Cefbiprole medocaril sodium, a broad‑spectrum fifth‑generation cephalosporin antibiotic. It binds to penicillin‑binding proteins of bacteria, blocks bacterial cell wall biosynthesis, and kills a wide range of gram‑positive and gram‑negative pathogens including MRSA.
Main Indications
Treatment of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) in adult patients;
Treatment of complicated skin and skin structure infections caused by susceptible microorganisms.
Clinical Research
Pivotal phase III trials confirmed that cefbiprole medocaril sodium was non-inferior to comparator antibiotics for hospital-acquired pneumonia and complicated skin and soft tissue infections. It maintains activity against methicillin-resistant Staphylococcus aureus, drug-resistant pneumococci and common Enterobacterales, achieving the primary clinical response endpoint with a manageable safety profile.
Common Side Effects
Gastrointestinal adverse reactions: nausea, vomiting, diarrhea;
Transient elevation of liver transaminases;
Other common reactions: headache, rash, pruritus and infusion-site reactions. Rare but serious anaphylactic hypersensitivity reactions may occur.
Approval Status in China
Original drug Zevtera® (Cefbiprole Medocaril Sodium for Injection) was officially approved for marketing in China in 2024, with the specification of 500mg per vial. It is currently a prescription drug.
Buy Zevtera (Cefbiprole Medocaril Sodium for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
